ASH 2012
4 interviews
American Society of Hematology Annual Meeting
Interviews and expert commentary from ASH 2012 — study authors and key opinion leaders discuss the findings and their clinical implications.
Chronic myeloid leukaemia: third generation TKI, ponatinib, succeeds against the T 315 I mutation
ATLANTA, GEORGIA—A “third generation” tyrosine kinase inhibitor — ponatinib — has succeeded in controlling chronic myeloid leukaemia and Philadelphia-positive acute lymphoblastic leukaemia
Acute promyelocytic leukaemia: arsenic better than chemotherapy to combine with retinoic acid?
ATLANTA, GEORGIA—Arsenic could play a key role in perfecting gentle but curative regimens for acute promyelocytic leukaemia, according to Italian researchers reporting to the 2012 American Society of
New drug looks very promising in high risk chronic lymphocytic leukaemia
ATLANTA, GEORGIA—The new tyrosine kinase ibrutinib has shown “profound activity” in patients with chronic lymphocytic leukaemia—according to research presented at the American Society of H
Lowering hematocrit below 45 per cent protects against clotting risk in patients with polycythemia vera — randomized study finding
ATLANTA, GA—Solid confirmation of target hematocrit to minimise clotting risks in polycythemia vera has been presented at the American Society of Hematology annual meeting and simultaneously published